Initiate synthesis and testing of novel PET ligands and develop and test novel CSF/blood biomarkers for assessment of disease related pathological burdens such as tau, inflammation, synaptic dysfunction.
Development and testing of 3-5 novel PET ligands and/or CSF/blood biomarkers for assessment of AD and ADRD pathology.
2014 to 2018
Research Implementation Area
B. Diagnosis, Assessment and Disease Monitoring